Aim: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell-cycle risk (CCR) score, a combined clinical and molecular score. Patients & methods: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. Results: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. Conclusion: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment.

Personalized medicine. 2019 Sep 04 [Epub ahead of print]

Sanjeev Kaul, Kirk J Wojno, Steven Stone, Brent Evans, Ryan Bernhisel, Stephanie Meek, Richard E D’Anna, Jeffrey Ferguson, Jeffrey Glaser, Todd M Morgan, Jeremy Lieb, Robert Yan, Todd Cohen, Behfar Ehdaie

Comprehensive Urology, Royal Oak, MI 48073, USA., Myriad Genetics, Inc., Salt Lake City, UT 84108, USA., Arkansas Urology, Little Rock, AR 72211, USA., Urological Associates, Colorado Springs, CO 80907, USA., Specialists in Urology, LLC, Lake Saint Louis, MO 63367, USA., Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA., Pacific Urology, Concord, CA 94520, USA., Golden Gate Urology, San Francisco, CA 94107, USA., Myriad Genetic Laboratories, Inc., Salt Lake City, UT 84108, USA., Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.